Tempest Therapeutics (NASDAQ:TPST) Downgraded by Zacks Research to Hold

Zacks Research downgraded shares of Tempest Therapeutics (NASDAQ:TPST) from a strong-buy rating to a hold rating in a report published on Thursday,Zacks.com reports.

Separately, Wall Street Zen downgraded Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tempest Therapeutics presently has an average rating of “Reduce”.

Tempest Therapeutics Stock Down 12.4%

Shares of TPST opened at $1.83 on Thursday. The company has a market cap of $26.24 million, a PE ratio of -0.30 and a beta of -1.75. The business has a fifty day moving average of $1.94 and a 200 day moving average of $3.35. Tempest Therapeutics has a 52-week low of $1.50 and a 52-week high of $12.23.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings results on Friday, May 15th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). As a group, research analysts anticipate that Tempest Therapeutics will post -1.34 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempest Therapeutics

In other Tempest Therapeutics news, CEO Matthew Angel bought 231,482 shares of the firm’s stock in a transaction dated Tuesday, March 24th. The stock was acquired at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the completion of the transaction, the chief executive officer owned 231,482 shares in the company, valued at $500,001.12. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.28% of the company’s stock.

Institutional Trading of Tempest Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TPST. Dimensional Fund Advisors LP bought a new stake in shares of Tempest Therapeutics during the fourth quarter worth $33,000. Sabby Management LLC bought a new stake in shares of Tempest Therapeutics during the fourth quarter worth $513,000. Finally, Vanguard Group Inc. lifted its position in shares of Tempest Therapeutics by 20.8% during the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after purchasing an additional 27,952 shares during the last quarter. 22.52% of the stock is currently owned by institutional investors.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.